5:20 PM
 | 
Nov 25, 2013
 |  BC Extra  |  Politics & Policy

FDA wants more transparency for meta-analyses

FDA held a workshop on Monday to discuss what requirements the agency should include in draft guidance on the design of meta-analyses of randomized controlled trials. Workshop attendees -- which included FDA officials, academics and industry representatives -- agreed that any meta-analysis submitted to the agency by...

Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >